Mark M. Smits

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Safety and Tolerability of SGLT2 Inhibitors.

Safety and Tolerability of SGLT2 Inhibitors.

Journal: Handbook of experimental pharmacology

Published: August 12, 2026

The gut microbial lauroyl tryptamine antagonizes oxysterol-GPR183 signaling to modulate lipid-sensitive metabolic pathways in a sex-dependent manner.

The gut microbial lauroyl tryptamine antagonizes oxysterol-GPR183 signaling to modulate lipid-sensitive metabolic pathways in a sex-dependent manner.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids

Published: January 06, 2026

Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.

Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.

Journal: The New England journal of medicine

Published: December 03, 2025

International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.

International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.

Journal: United European gastroenterology journal

Published: September 01, 2025

Beyond a singular focus on GLP-1: why we need a new nomenclature now.

Beyond a singular focus on GLP-1: why we need a new nomenclature now.

Journal: The lancet. Diabetes & endocrinology

Published: June 23, 2025

Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.

Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.

Journal: Lancet (London, England)

Published: April 11, 2025

Single incretin receptor knockout mice do not compensate by increasing glucose-stimulated secretion of the remaining incretin hormone.

Single incretin receptor knockout mice do not compensate by increasing glucose-stimulated secretion of the remaining incretin hormone.

Journal: American journal of physiology. Endocrinology and metabolism

Published: February 11, 2025

The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals.

The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals.

Journal: Journal of nephrology

Published: December 24, 2024

Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet.

Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet.

Journal: Physiological reports

Published: December 02, 2024

Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?

Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?

Journal: Current opinion in lipidology

Published: July 31, 2024

Alpha-cyclodextrin increases glucagon-like peptide-1 secretion in multiple models and improves metabolic status in mice.

Alpha-cyclodextrin increases glucagon-like peptide-1 secretion in multiple models and improves metabolic status in mice.

Journal: Food chemistry

Published: February 26, 2024

L-valine is a powerful stimulator of GLP-1 secretion in rodents and stimulates secretion through ATP-sensitive potassium channels and voltage-gated calcium channels.

L-valine is a powerful stimulator of GLP-1 secretion in rodents and stimulates secretion through ATP-sensitive potassium channels and voltage-gated calcium channels.

Journal: Nutrition & diabetes

Published: January 23, 2024

Showing 1-12 of 93

Last Updated: 09/26/2026